Genetics, Genotype, In-Vivo and Protein - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Genetics

Genotype

In-Vivo

Protein

Innovative Companies Diving into The Neuro Market Ahead of 2021

The Pharma Data

DECEMBER 9, 2020

Vigil’s pipeline strategy is to target these diseases by combining a high-level understanding of microglia physiology, disease genotyping, and patient phenotyping to identify specific genetic variations associated with microglial dysfunction. which will remain a key shareholder. SciNeuro Pharmaceuticals. in a statement. .

Marketing

Marketing In-Vivo Protein In-Vitro

RNA editing oligonucleotide selected for AATD treatment

Drug Discovery World

DECEMBER 12, 2023

Context and treatment potential AATD is an inherited, autosomal recessive genetic disorder that is most frequently caused by a single nucleotide variant (SNV) mutation in the SERPINA1 gene, the most common of which is the ‘PiZ’ mutation. I look forward to having access to this therapy as quickly as possible.”

RNA

RNA In-Vivo Genotype Genetics

Innovative Companies Diving into The Neuro Market Ahead of 2021

RNA editing oligonucleotide selected for AATD treatment

Stay Connected